On Sept. 15, 2020, Innovation Pharma reported additional data from a U.S. Regional Biocontainment Laboratory (RBL) collected during ongoing in vitro testing supporting Brilacidin as a potential treatment for SARS-CoV-2. Overall viral load was reduced by 99.85 percent in one combination experiment, with remaining virus dropping to near undetectable levels.